metabolic associated fatty liver disease
Conditions
Interventions
Experimental group:Simepaglutide
Sponsors
the Second People's Hospital of Chizhou
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Voluntarily sign the informed consent before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly comply with the clinical trial protocol to complete this trial; ? Meet the diagnosis of T2DM; ? Meet the diagnosis of MAFLD: based on liver biopsy histology, imaging or blood biomarker tests suggesting the presence of fatty liver, and at the same time meet one of the following three conditions: overweight/obesity, type 2 diabetes mellitus, metabolic dysfunction. ? Age > 18 years; ? Renal function (eGFR) > 15 mL/min/1.73 m2 ? Participants need to minimize weight gain or promote weight loss as much as possible.
Exclusion criteria
Exclusion criteria: ? Other forms of diabetes are excluded; ? Subjects who may be allergic or intolerant to the study drug; ? Persons of childbearing age with a requirement for pregnancy (within one year), pregnant women and lactating women; ? Subjects with poor compliance ? Exclusion of viral hepatitis B or C, and excessive alcohol consumption (more than 30 g/day for men and 20 g/day for women); ? Suspected high risk of pancreatitis or previous history of pancreatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver stiffness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood test;Urine routine;Fasting blood glucose;HbA1c;2 hours postprandial blood glucose;Fasting C peptide;Fasting insulin (medicine);C-peptide 2 hours postprandial;2 hours postprandial insulin;Liver function;Renal function;Visceral fat index;Lipid accumulation products;Liver fibrosis index;CRP; | — |
Countries
China
Contacts
Public Contactzhufengping; xuyiqi
the Second People's Hospital of Chizhou
Outcome results
None listed